Received Sep 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 7NA57 | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | L4EA4 | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | GB73Y | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Across vaccines- Administration to patients after a temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a patient who received Men ACWY-CRM NVS (Menveo) (batch number GB73Y) and (batch number DL4YY) for prophylaxis. Co-suspect products included Men B NVS (Bexsero) for prophylaxis, HBV (Engerix B) (batch number 7NA57) for prophylaxis, HAV (Havrix pediatric) (batch number L4EA4) for prophylaxis, DTPa-HBV-IPV (Pediarix) for prophylaxis, DTPa (Reduced antigen) (Boostrix) for prophylaxis and DTPa-IPV (Kinrix) for prophylaxis. On an unknown date, the patient received Menveo. On an unknown date, the patient received Bexsero, Engerix B, Havrix pediatric, Pediarix, Boostrix and Kinrix. On an unknown date, an unknown time after receiving Menveo, Bexsero, Engerix B, Havrix pediatric, Pediarix, Boostrix and Kinrix, the patient experienced incorrect storage of drug (Verbatim: Across vaccines- Administration to patients after a temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-AUG-2025 The medical assistant has found a temperature excursion for Menveo, Bexsero, Engerix-B, Havrix, Pediarix, Boostrix and Kinrix vaccines back. Highest temperature reached was 52.3 degree Fahrenheit, lowest was 38.1 degree Fahrenheit Vaccines were out of temperature range for 2 hours and 50 minutes. These vaccines have not been in any other temperature excursion. Since the vaccines have been administer to patients until today 21st August 2025 which led to incorrect storage of drug. The vaccine administration facility was the same as primary.